TY - JOUR T1 - Observational study of inhaled corticosteroid treatment for improved expiratory variability index in steroid-naive asthmatic children JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00499-2021 SP - 00499-2021 AU - Janne Burman AU - Pekka Malmberg AU - Ville-Pekka Seppä AU - Tuomas Jartti AU - Sami Remes AU - Ove Mickelsson AU - Anna S. Pelkonen AU - Mika J Mäkelä Y1 - 2021/01/01 UR - http://openres.ersjournals.com/content/early/2021/11/11/23120541.00499-2021.abstract N2 - The Lancet Asthma Commission calls for objective measurements to support asthma diagnosis, especially for children [1]. The expiratory variability index (EVI) is a novel method of testing lung function testing that can be measured passively at night with an impedance pneumography (IP) technique using four skin electrodes and a small body-worn recorder. The aim of EVI is to measure variation in flow-volume curve shapes within 15–45% of the expired volume. It has been demostrated that normal variations in the curve shapes are mainly caused by comparing different sleep cycles [2], which are reduced in the presence of bronchial obstructions [3].FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Janne Burman reports support for the present manuscript from Allergy Research Foundation, Jalmari and Rauha Ahokas Foundation (Helsinki), Helsinki Region Allergy Foundation (Helsinki), the Culture Foundation, The Sigrid Juselius Foundation, and Revenio Research Ltd.Conflict of interest: Pekka Malmberg reports support for the present manuscript from Allergy Research Foundation, Jalmari and Rauha Ahokas Foundation (Helsinki), Helsinki Region Allergy Foundation (Helsinki), the Culture Foundation, The Sigrid Juselius Foundation, and Revenio Research Ltd.Conflict of interest: Ville-Pekka Seppä reports support for the present manuscript from Allergy Research Foundation, Jalmari and Rauha Ahokas Foundation (Helsinki), Helsinki Region Allergy Foundation (Helsinki), the Culture Foundation, The Sigrid Juselius Foundation, and Revenio Research Ltd. Ville-Pekka Seppä reports to be an employee of Revenio Group corporation that commercialized IP technology. Ville-Pekka Seppä also reports to hold patent relating to impedance pneumography, no further details provided.Conflict of interest: Tuomas Jartti reports support for the present manuscript from Allergy Research Foundation, Jalmari and Rauha Ahokas Foundation (Helsinki), Helsinki Region Allergy Foundation (Helsinki), the Culture Foundation, The Sigrid Juselius Foundation, and Revenio Research Ltd.Conflict of interest: Sami RemesConflict of interest: Ove Mickelsson reports support for the present manuscript from Allergy Research Foundation, Jalmari and Rauha Ahokas Foundation (Helsinki), Helsinki Region Allergy Foundation (Helsinki), the Culture Foundation, The Sigrid Juselius Foundation, and Revenio Research Ltd.Conflict of interest: Anna Pelkonen reports support for the present manuscript from Allergy Research Foundation, Jalmari and Rauha Ahokas Foundation (Helsinki), Helsinki Region Allergy Foundation (Helsinki), the Culture Foundation, The Sigrid Juselius Foundation, and Revenio Research Ltd.Conflict of interest: Mika Mäkelä reports support for the present manuscript from Allergy Research Foundation, Jalmari and Rauha Ahokas Foundation (Helsinki), Helsinki Region Allergy Foundation (Helsinki), the Culture Foundation, The Sigrid Juselius Foundation, and Revenio Research Ltd.Conflict of interest: Leo Malmberg reports support for the present manuscript from Allergy Research Foundation, Jalmari and Rauha Ahokas Foundation (Helsinki), Helsinki Region Allergy Foundation (Helsinki), the Culture Foundation, The Sigrid Juselius Foundation, and Revenio Research Ltd. ER -